AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04667598
Drug: Modified Wenxin Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.
Trial: NCT01732510
Drug: MK-8226
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
Trial: NCT01732510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered IV every 2 weeks for a period of 12 weeks.
Trial: NCT00119769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 0.7 mg/day injected subcutaneously
Trial: NCT00640809
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg oral capsule twice daily for 2 weeks
Trial: NCT00640809
Drug: Ibuprofen plus Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks
Trial: NCT00488449
Drug: GSK256073A tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03026231
Drug: Placebo (for PRIM-DJ2727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
Trial: NCT02365610
Drug: GWP42006
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02365610
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04532294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match BGB-DXP593
Trial: NCT02561481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See under placebo arm description
Trial: NCT00002552
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002552
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002552
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002552
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03909906
Drug: Euphytose®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (50mg Valeriana officinalis L., 40mg Passiflora incarnate L., 10mg Crataegus sp., 10mg Ballota nigra L.)
Trial: NCT03909906
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT03098537
Drug: enteral nutrition + proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive enteral nutrition and proton pump inhibitor
Trial: NCT00537381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
Trial: NCT02511795
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14.
Trial: NCT02016716
Drug: Placebo 90 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.
Trial: NCT02016716
Drug: Placebo 70 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
Trial: NCT02553551
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given.
Trial: NCT00731770
Drug: Advair 250
RxNorm normalized name: Advair 250/50 Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 puff bid inhaled
Trial: NCT00731770
Drug: Placebo- matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 puff bid inhaled
Trial: NCT00731770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 puff bid inhaled
Trial: NCT00978419
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
Trial: NCT00978419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered every day for up to 28 days
Trial: NCT04548700
Drug: Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 15 mg/m2, 18 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28-day cycle.
Trial: NCT04548700
Drug: Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Liposomal mitoxantrone hydrochloride (at RP2D) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28- or 21-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28- or 21-day.
Trial: NCT02142400
Drug: DS-1093
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1093 in capsules with 2.5mg or 25mg per capsule
Trial: NCT00811577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
Trial: NCT02142400
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo capsules to DS-1093 capsules
Trial: NCT00811577
Drug: AZX100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZX100 Drug Product 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
Trial: NCT01631669
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg Q 12 hours orally
Trial: NCT01034982
Drug: AZD9668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg
Trial: NCT01034982
Drug: AZD9668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg
Trial: NCT02147197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet.
Trial: NCT01321255
Drug: Separately drugs, simvastatin, aspirin and ramipril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg once a day Ramipril 2.5; 5; 10 mg once a day Simvastatin 40 mg once a day
Trial: NCT01700959
Drug: melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.
Trial: NCT01700959
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to match the melatonin will be comprised of inert substances.
Trial: NCT00298441
Drug: chondroitin sulfate-iron colloid
RxNorm normalized name: chondroitin sulfate-iron complex
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00255918
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dosed to match active medication
Trial: NCT02897037
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: heparin monotherapy
Trial: NCT02482428
Drug: Investigational Treatment
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied twice daily for up to 12 weeks
Trial: NCT00039780
Drug: BNP7787
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
Trial: NCT00039780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
Trial: NCT00945347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal instillation of placebo matching in appearance with the Miglustat instillation
Trial: NCT02407080
Drug: RG7388
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.
Trial: NCT01283776
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation
Trial: NCT03347526
Drug: Cosyntropin Injectable Suspension, 1 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable
Trial: NCT02479087
Drug: Plasma-derived FVIII/VWF concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational treatment is with lyophilized plasma-derived Factor VIII. The product belongs to the factor VIII concentrates class, containing also VW Factor in an average ratio VW/VIII of \> 1: 4.5.~The product is as a powder and a solvent solution for continuous infusion of Factor VIII. The specific activity of Factor VIII is of approximately 80 IU/mg protein.~The number of units of FVIII administered is expressed in International Units (IU), which are consistent with current WHO standards for products containing Factor VIII. The activity of Factor VIII in plasma is expressed either as a percentage (compared to normal human plasma) or in International Units (compared to the international standard for FVIII in plasma).
Trial: NCT01097265
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03462927
Drug: MC2-01 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)
Trial: NCT03462927
Drug: CAL/BDP combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)
Trial: NCT01422785
Drug: clindamycin phosphate 1.2%/tretinoin 0.025% gel alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application of the clindamycin phosphate 1.2%/tretinoin 0.025% gel in the evening
Trial: NCT01422785
Drug: clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wash face with the benzoyl peroxide foaming cloth then rinse. then apply clindamycin phosphate 1.2%/tretinoin 0.025% gel. both done in the evening.
Trial: NCT01748812
Drug: Osteomalacia
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04410562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a bottle containing 19 tablets of placebo. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days.
Trial: NCT02912494
Drug: JR-131
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01109121
Drug: Combination 400
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranilast 300 mg QD; Allopurinol 400 mg QD
Trial: NCT01109121
Drug: Combination 600
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranilast, 300 mg QD; Allopurinol 600 mg QD
Trial: NCT01157572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with moderate to severe aortic valve insufficiency will be randomized to Placebo
Trial: NCT00104416
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control
Trial: NCT01450696
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered at a dose of 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
Trial: NCT03668496
Drug: The placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in the control group,placebo was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
Trial: NCT00883168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00000149
Drug: Beta Blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04296305
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV after
Trial: NCT00505973
Drug: SCA-136
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01804933
Drug: profound neuromuscular blockade
RxNorm normalized name: Profender
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\~2 intraoperatively
Trial: NCT00887367
Drug: GSK598809
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 175 mg doses of GSK598809 will be given.
Trial: NCT03668470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: one injection per week during 24 weeks
Trial: NCT01920919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00323960
Drug: 3 MPDN pulse + PDN
RxNorm normalized name: DULSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.
Trial: NCT02385084
Drug: LY2409021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04664933
Drug: Intra-arterial administration of neuroprotective agents
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min
Trial: NCT02866006
Drug: BVAC-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous B cells and monocytes transfected with E6E7 gene of HPV
Trial: NCT01162824
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incremental doses of 2, 20 and 100 µg of ACH will be injected into the left coronary artery (LCA) via the diagnostic catheter for 3 minutes each. After that 80 µg of ACH will be injected into the right coronary artery. Coronary angiography will be performed after each 3 minute dose period. After the test or when intolerable chest pain due to coronary spasm occurs, 0.2 mg of glyceryltrinitrate will be injected into each vessel. During the test, heart rate, blood pressure and ECG will be monitored continuously.
Trial: NCT01162824
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coronary blood flow velocity measurements will be performed in the mid segment of the left anterior descending artery with a 0.014-in intracoronary Doppler guidewire connected to the corresponding interface. Measurements will be obtained after the administration of nitroglycerin, at baseline and during maximal hyperaemia. Sustained intravenous administration of adenosine - an arteriolar vasodilator- will be used to induce maximal hyperaemia (140-180µg/kg/min).
Trial: NCT01127464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
Trial: NCT00479817
Drug: AMG 386 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 386 Placebo
Trial: NCT00330980
Drug: 40 mg Pravastatin (Pravachol)
RxNorm normalized name: pravastatin sodium 40 MG [Pravachol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 40 mg of pravastatin for 6 months.
Trial: NCT00330980
Drug: 20 mg Simvastatin
RxNorm normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 20 mg of simvastatin for 6 months.
Trial: NCT00330980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo for 6 months.
Trial: NCT00256360
Drug: dose dense with neulasta
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03160248
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study aims on investigating the efficacy of Apremilast in nummular eczema patients - placebo controlled
Trial: NCT02910752
Drug: CLAM+PBSC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
Trial: NCT02765815
Drug: Bupivacaine 0.5 % with Epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02765815
Drug: Ketorolac 30mg
RxNorm normalized name: ketorolac 30 MG
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02765815
Drug: Bupivacaine 0.25% with Epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02262026
Drug: 125 mg AZD0530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to receive 125 mg of AZD0530
Trial: NCT02262026
Drug: 50 mg AZD0530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to receive 50 mg of AZD0530
Trial: NCT02262026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00019968
Drug: tumor necrosis factor
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00869791
Drug: IPX066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental drug product: extended-release carbidopa-levodopa capsules
Trial: NCT00869791
Drug: IR CD-LD
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active comparator: immediate-release carbidopa-levodopa capsules
Trial: NCT00800527
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac 75 mg one a day up to 30 day
Trial: NCT01541904
Drug: PRO-118 Ophthalmic Solution 0.015%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days
Trial: NCT01541904
Drug: PRO-118 Ophthalmic Solution 0.015 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days
Trial: NCT01541904
Drug: PRO-118 Ophthalmic Solution 0.020 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days
Trial: NCT01541904
Drug: PRO-118 Ophthalmic Solution 0.020 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days
Trial: NCT01541904
Drug: Placebo Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Ophthalmic Solution applied qd during 21 days
Trial: NCT01369472
Drug: Dilatrend SR capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration in period 1 or 2, 3 for each sequential group.
Trial: NCT03874741
Drug: SCT200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression~Other Names:~• SCT200
Trial: NCT02963168
Drug: Oradoxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets
Trial: NCT00313144
Drug: ARALAST Alpha1-Proteinase Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly ARALAST infusions for 2 years, dose and mode of administration as prescribed by the physician